 |
|
The Search for a Magic Bullet to Fight Sepsis
Roger C. Bone, MD
JAMA. 1993;269(17):2266-2267.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Recently, excitement among the clinical researchers trying to identify additional treatments for sepsis and its associated disorders reached a fever pitch after the publication of two controlled, multicenter clinical trials of monoclonal antibodies against endotoxin. The results of these trials indicated that these antibodies could improve survival in some subgroups of patients suspected of having gram-negative sepsis.1,2
See also p 2221.
These trials followed an earlier study that showed that antisera from volunteers injected with the J5 Escherichia coli mutant could improve survival in patients with gram-negative sepsis.3 Because of these studies, it was widely perceived that Food and Drug Administration approval of one or both of these antibodies would be imminent following publication of the controlled clinical trial results. Clinicians and clinical investigators attempted to develop guidelines for the appropriate use of these therapies—albeit among patients most likely to benefit—so that if approved, they would be used
. . . [Full Text PDF of this Article]
Author Affiliations
From the Section of Pulmonary Medicine, Department of Internal Medicine, Rush-Presbyterian-St Luke's Medical Center, and Rush Medical College, Chicago, Ill,
Footnotes
Reprint requests to Department of Internal Medicine, Rush-Presbyterian-St Luke's Medical Center, 1753 W Congress Pkwy, Chicago, IL 60612 (Dr Bone).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
